These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33504008)

  • 1. Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach.
    Gelemanović A; Vidović T; Stepanić V; Trajković K
    Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33504008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.
    Mousavi SZ; Rahmanian M; Sami A
    Infect Genet Evol; 2020 Dec; 86():104610. PubMed ID: 33130005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19.
    Islam T; Rahman MR; Aydin B; Beklen H; Arga KY; Shahjaman M
    Eur J Pharmacol; 2020 Nov; 887():173594. PubMed ID: 32971089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico drug repurposing against SARS-CoV-2 using an integrative transcriptomic profiling approach: Hydrocortisone and Benzhydrocodone as potential drug candidates against COVID-19.
    Mirmohammadi S; Kianmehr A; Sabbaghian A; Mohebbi A; Shahbazmohammadi H; Sheykharabi M; Bazzi Z
    Infect Genet Evol; 2022 Sep; 103():105318. PubMed ID: 35718334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach.
    Loganathan T; Ramachandran S; Shankaran P; Nagarajan D; Mohan S S
    PeerJ; 2020; 8():e9357. PubMed ID: 32566414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing.
    Krishnamoorthy P; Raj AS; Roy S; Kumar NS; Kumar H
    Comput Biol Med; 2021 Jan; 128():104123. PubMed ID: 33260034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing.
    Maria NI; Rapicavoli RV; Alaimo S; Bischof E; Stasuzzo A; Broek JAC; Pulvirenti A; Mishra B; Duits AJ; Ferro A;
    Heliyon; 2023 Mar; 9(3):e14115. PubMed ID: 36911878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2.
    Bess A; Berglind F; Mukhopadhyay S; Brylinski M; Alvin C; Fattah F; Wasan KM
    Front Pharmacol; 2023; 14():1297924. PubMed ID: 38186640
    [No Abstract]   [Full Text] [Related]  

  • 9. In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data.
    Das S; Camphausen K; Shankavaram U
    Res Sq; 2020 Jun; ():. PubMed ID: 32702730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Identification of Druggable Targets and the Power of the PHENotype SIMulator for Effective Drug Repurposing in COVID-19.
    Maria NI; Rapicavoli RV; Alaimo S; Bischof E; Stasuzzo A; Broek JAC; Pulvirenti A; Mishra B; Duits AJ; Ferro A
    Res Sq; 2021 Apr; ():. PubMed ID: 33880466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network bioinformatics analysis provides insight into drug repurposing for COVID-19.
    Li X; Yu J; Zhang Z; Ren J; Peluffo AE; Zhang W; Zhao Y; Wu J; Yan K; Cohen D; Wang W
    Med Drug Discov; 2021 Jun; 10():100090. PubMed ID: 33817623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Repurposable Drugs and Adverse Drug Reactions for Various Courses of COVID-19 Based on Single-Cell RNA Sequencing Data.
    Wang Z; Guo K; Gao P; Pu Q; Wu M; Li C; Hur J
    ArXiv; 2020 May; ():. PubMed ID: 33299905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Infected Host Gene Expression Reveals Repurposed Drug Candidates and Time-Dependent Host Response Dynamics for COVID-19.
    Xing J; Shankar R; Drelich A; Paithankar S; Chekalin E; Dexheimer T; Chua MS; Rajasekaran S; Tseng CK; Chen B
    bioRxiv; 2020 Jun; ():. PubMed ID: 32511305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19.
    Le BL; Andreoletti G; Oskotsky T; Vallejo-Gracia A; Rosales R; Yu K; Kosti I; Leon KE; Bunis DG; Li C; Kumar GR; White KM; García-Sastre A; Ott M; Sirota M
    Sci Rep; 2021 Jun; 11(1):12310. PubMed ID: 34112877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Coronavirus Network Explorer: mining a large-scale knowledge graph for effects of SARS-CoV-2 on host cell function.
    Krämer A; Billaud JN; Tugendreich S; Shiffman D; Jones M; Green J
    BMC Bioinformatics; 2021 May; 22(1):229. PubMed ID: 33941085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic risk factors for severe and fatigue dominant long COVID and commonalities with ME/CFS identified by combinatorial analysis.
    Taylor K; Pearson M; Das S; Sardell J; Chocian K; Gardner S
    J Transl Med; 2023 Nov; 21(1):775. PubMed ID: 37915075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.
    Ahmed FF; Reza MS; Sarker MS; Islam MS; Mosharaf MP; Hasan S; Mollah MNH
    PLoS One; 2022; 17(4):e0266124. PubMed ID: 35390032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19.
    Le BL; Andreoletti G; Oskotsky T; Vallejo-Gracia A; Rosales R; Yu K; Kosti I; Leon KE; Bunis DG; Li C; Kumar GR; White KM; García-Sastre A; Ott M; Sirota M
    Res Sq; 2021 Mar; ():. PubMed ID: 33821262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.
    Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H
    Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.